利拉鲁肽对腹型肥胖2型糖尿病患者内脏脂肪面积的影响

Effect of Liraglutide on Visceral Fat Area in Patients with Abdominal Obesity Type 2 Diabetes

目的探讨利拉鲁肽治疗腹型肥胖的2型糖尿病(T2DM)患者的效果及对内脏脂肪面积的影响。方法选取我院内分泌科收治的100例腹型肥胖的T2DM患者作为研究对象,采用随机数字表法分为治疗组和对照组各50例;两组患者均给予常规降血糖药物治疗、控制饮食等,治疗组同时皮下注射利拉鲁肽治疗;对比两组治疗前后的体质指数(BMI)、腰围(WC)、臀围、腰臀比、内脏脂肪面积、空腹血糖(FPG)、餐后2h血糖(2hPG)、糖化血红蛋白(Hb A1c)、不良反应发生率。结果治疗前,治疗组和对照组的BMI、WC、臀围、腰臀比测定值差异无统计学意义(P>0.05);治疗后,治疗组患者的BMI、WC、腰臀比均低于对照组(P<0.05);治疗前,治疗组和对照组的FPG、2hPG、Hb A1c测定值差异无统计学意义(P>0.05);治疗后,治疗组患者的FPG、2hPG、Hb A1c测定值均低于对照组(P<0.05);治疗前,治疗组和对照组的内脏脂肪面积差异无统计学意义(P>0.05);治疗后,治疗组患者的内脏脂肪面积低于对照组(P<0.05)。治疗过程中,两组患者均未出现严重的不良反应,治疗组有5例出现轻度不适,对照组有1例出现轻度不适,两组不良反应发生率差异无统计学意义(P>0.05)。结论利拉鲁肽治疗腹型肥胖的T2DM患者有利于降低内脏脂肪面积,改善患者的肥胖效果较为显著。

Objective To investigate the effect of liraglutide on abdominal obesity in patients with type 2 diabetes mellitus( T2 DM) and its effect on visceral fat area.Methods 100 T2 DM patients with abdominal obesity in endocrinology department of our hospital were selected as research object.They were divided intotreatment group( TG,n = 50) and control group( CG,n = 50).All patients were given conventional hypoglycemic drugs and diet control.At the same time,TG was given subcutaneous injection of liraglutide.The body mass index( BMI),waist circumference( WC),hip circumference( HC),waist-hip ratio,visceral fat area,fasting blood glucose( FPG),postprandial 2 h blood glucose( 2 hPG),glycosylated hemoglobin( Hb A1 c) and adverse reaction rate were compared before and after treatment. Results Before treatment,there were no significant differences in BMI,WC,HC and waist-hip ratio between two groups( P > 0. 05). After treatment,BMI,WC and waist-hip ratio of TG were all lower than CG( P <0. 05).Before treatment,there was no significant difference in FPG,2 hPG,and Hb A1 c between TGand CG( P>0. 05).After treatment,FPG,2 hPG,and Hb A1 c of TG were lower than those of CG( P<0. 05).Before treatment,there was no significant difference in the area of visceral fat between TGand CG( P> 0. 05). After treatment,thevisceral fat area of TG was lower than that of CG( P<0. 05).During the treatment course,there were no serious adverse reactions.There were 5 cases of mild discomfort in TG and 1 case of mild discomfort in CG.There was no statistical difference in the incidence of adverse reactions( P>0. 05).Conclusion Liraglutide treatment of T2 DM patients with abdominal obesity is beneficial to reduce visceral fat area and has a significant effect in improving the obesity.